QQX — Respiratory Specimen Nucleic Acid Sars-Cov-2 Test Class II

FDA Device Classification

Classification Details

Product Code
QQX
Device Class
Class II
Regulation Number
866.3981
Submission Type
Review Panel
MI
Medical Specialty
Microbiology
Implant
No

Definition

A device to detect and identify nucleic acid targets in respiratory specimens from SARS-CoV-2 that cause COVID-19 is an in vitro diagnostic device intended for the detection and identification of SARS-CoV-2 nucleic acid targets in human clinical respiratory specimens from patients suspected of COVID-19 based on signs and symptoms of respiratory infections by their healthcare providers. The device is intended to aid in the diagnosis of COVID-19 in conjunction with other clinical, epidemiologic, and laboratory data or other risk factors.

Recent 510(k) Clearances

K-NumberApplicantDevice NameDate
K243396hologicAptima SARS-CoV-2 AssayFebruary 13, 2025
K240867roche molecular systemscobas® SARS-CoV-2 Qualitative for use on the cobas® 5800/6800/8800 SystemsFebruary 11, 2025
K242109cepheid®Xpert® Xpress CoV-2 plus (XPRS-COV2-10)January 15, 2025
K241580abbott molecularAlinity m SARS-CoV-2 AMP Kit (09N78-096); Alinity m SARS-CoV-2 CTRL Kit (09N78-0December 6, 2024
K233453life technologies corporationApplied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR KitJuly 10, 2024
K230440cepheid®Xpert® Xpress CoV-2 plusOctober 13, 2023
K231306roche molecular systemscobas SARS-CoV-2 Qualitative for use on the cobas 5800/6800/8800 SystemsJune 1, 2023
K213804roche molecular systemscobas SARS-CoV-2 Qualitative for use on the cobas 6800/8800 SystemsOctober 22, 2022
K212147diasorin molecularSimplexa COVID-19 DirectSeptember 13, 2022
K221460biofire defenseBioFire COVID-19 Test 2July 25, 2022
K211079biofire defenseBioFire COVID-19 Test 2November 1, 2021